加载中
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
前收盘价
US$4.23
−US$0.33 · -7.24%
盘前
US$4.25
+US$0.02 · +0.47%
10月12日 7:10 ET
盘中时间采用ET。市场数据可能有所延迟。
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
日内区间
当前US$4.23
52周区间
当前US$4.23
盘中时间采用ET。市场数据可能有所延迟。
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
日内区间
当前US$4.23
52周区间
当前US$4.23
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 8427.8万 USD | 8914.9万 USD | 3万 USD | 131.6万 USD | 550.6万 USD |
| 销货成本 | 2042.3万 USD | 2055.7万 USD | — | 1712万 USD | 21.3万 USD |
| 毛利 | 6385.5万 USD | 6859.2万 USD | 3万 USD | −1580.4万 USD | 529.3万 USD |
| 研究与开发 | 1318.1万 USD | 1958万 USD | 2026.6万 USD | 1837.6万 USD | 2027.3万 USD |
| 销售、一般及管理费用 | 2.3亿 USD | — | 4728.4万 USD | 1865.6万 USD | 468.7万 USD |
| 营业费用 | 2.43亿 USD | 7167.5万 USD | 6755万 USD | 1971.2万 USD | 2474.7万 USD |
| 利息收入 | 1066.9万 USD | — | — | — | 80万 USD |
| 利息支出 | 259.9万 USD | — | — | — | 10.6万 USD |
| 折旧和摊销 | 136.7万 USD | 7.9万 USD | 7.3万 USD | 31.9万 USD | 21.3万 USD |
| 营业利润 | −1.79亿 USD | −308.3万 USD | −6752万 USD | −3551.6万 USD | −1945.4万 USD |
| 净利润 | −1.71亿 USD | 799.8万 USD | −5436.5万 USD | −3468.2万 USD | −2024.3万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1049.86万0.00%2.3万亿 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1005.55万0.10%98.74亿 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM749.61万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF457.69万0.00%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO262.75万0.02%139.17亿 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB221.2万0.02%108.2亿 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO212.59万0.01%180亿 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA154.42万0.01%218.24亿 USD0.03%US$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
